Concord Biotech Complete Financial Statements
CONCORDBIO • Review detailed financials to uncover trends, confirm thesis & journal trades
6 Years of Data
2025 - 2020
Complete Financial Data Export
Export complete financial statements for Concord Biotech (CONCORDBIO).
Downloads include all available records across all periods.
For market performance, see the
CONCORDBIO stock price today
.
Profitability Ratios
Net Profit Margin
23.95%
2025 data
EBITDA Margin
39.54%
2025 data
Operating Margin
36.00%
2025 data
Return on Assets
3.10%
2025 data
Return on Equity
3.47%
2025 data
Balance Sheet Ratios
Current Ratio
29.87
2025 data
Debt to Equity
1.12
2025 data
Equity Ratio
89.13%
2025 data
Asset Turnover
0.13
2025 data
Year-over-Year Growth Analysis
Comparing Sept 2024 vs Sept 2025
Revenue Growth
-17.8%
Year-over-Year
Net Profit Growth
-34.4%
Year-over-Year
EBITDA Growth
-27.8%
Year-over-Year
Expense Growth
-10.2%
Year-over-Year
Assets Growth
+19.6%
Year-over-Year
Equity Growth
+18.7%
Year-over-Year
Liabilities Growth
+19.6%
Year-over-Year
Operating Cash Flow Growth
-7.9%
Year-over-Year
Investing Cash Flow Growth
-3.2%
Year-over-Year
Income Statement
Periods
₹ Crores
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Jun 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 263 | 439 | 219 | 320 | 330 | 228 | 261 | 271 | 285 | 208 | 252 | 165 | 195 | 250 |
| Expenses | 159 | 241 | 143 | 177 | 187 | 135 | 146 | 147 | 146 | 123 | 135 | 122 | 116 | 131 |
| EBITDA | 104 | 198 | 77 | 144 | 143 | 93 | 115 | 124 | 139 | 85 | 117 | 44 | 79 | 119 |
| Operating Profit Margin % | 36.00% | 44.00% | 30.00% | 43.00% | 41.00% | 38.00% | 40.00% | 44.00% | 47.00% | 37.00% | 44.00% | 24.00% | 36.00% | 46.00% |
| Depreciation | 18 | 15 | 18 | 13 | 14 | 13 | 13 | 13 | 14 | 13 | 14 | 13 | 14 | 14 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 86 | 184 | 59 | 130 | 129 | 80 | 101 | 110 | 124 | 71 | 103 | 30 | 64 | 105 |
| Tax | 23 | 43 | 15 | 35 | 34 | 20 | 25 | 29 | 32 | 17 | 26 | 8 | 15 | 27 |
| Net Profit | 63 | 140 | 44 | 96 | 95 | 60 | 76 | 81 | 92 | 55 | 78 | 22 | 49 | 77 |
| Earnings Per Share (₹) | 6.03 | 13.42 | 4.21 | 9.15 | 9.08 | 5.70 | 7.26 | 7.74 | 8.75 | 5.21 | 7.41 | 2.10 | 4.71 | 7.40 |
Related Pages for Concord Biotech
Additional stock information and data for CONCORDBIO
Balance Sheet
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Total Assets | 2,034 | 1,701 | 1,514 | 1,313 | 941 |
| Current Assets | 1,135 | 896 | 728 | 633 | 539 |
| Fixed Assets | 795 | 575 | 593 | 573 | 240 |
| Capital Work in Progress | 51 | 212 | 173 | 74 | 141 |
| Investments | 335 | 246 | 137 | 74 | 199 |
| Other Assets | 854 | 668 | 611 | 592 | 361 |
| LIABILITIES | |||||
| Total Liabilities | 2,034 | 1,701 | 1,514 | 1,313 | 941 |
| Current Liabilities | 38 | 32 | 32 | 54 | 55 |
| Non-Current Liabilities | |||||
| SHAREHOLDERS' EQUITY | |||||
| Total Equity | 1,813 | 1,527 | 1,290 | 1,103 | 770 |
| Share Capital | 11 | 11 | 11 | 10 | 10 |
| Reserves & Surplus | 1,802 | 1,516 | 1,280 | 1,094 | 761 |
Cash Flow Statement
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 |
|---|---|---|---|---|---|---|
| Operating Activities | 245 | 266 | 246 | 208 | 167 | 155 |
| Investing Activities | -160 | -155 | -158 | -112 | -195 | -114 |
| Financing Activities | -99 | -99 | -85 | -100 | 31 | -43 |
| Net Cash Flow | -14 | 12 | 3 | -5 | 3 | -1 |